Brief: Tourmaline Bio's cash position to provide cash runway into second half of 2027
13/03/2025 11:39
March 13 (Reuters) - Tourmaline Bio Inc TRML.O: TOURMALINE BIO INC: EXPECTED CASH RUNWAY INTO SECOND HALF OF 2027 TOURMALINE BIO INC Q4 LOSS PER SHARE $0.86 Source text: ID:nGNXfNLdT Further company coverage: TRML.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy